Sign In
Buy ARDX
$6.18
-0.190 (-2.98%)
At Close: Jun 23, 2026
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi
The 3 Best Penny Stocks to Buy in May 2024
04:00pm, Sunday, 19'th May 2024
Penny stocks are classified as stocks that trade for less than $5 and are typically some of the riskiest stocks on the market. Many deserve their extremely low valuations, and investors avoid them as
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
08:01am, Thursday, 16'th May 2024
WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi
Ardelyx, Inc. Reports Employment Inducement Grants
04:02pm, Tuesday, 14'th May 2024
WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi
Ardelyx, Inc. (ARDX) Q1 2024 Earnings Call Transcript
11:14pm, Thursday, 02'nd May 2024
Ardelyx, Inc. (NASDAQ:ARDX ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - Pr
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
06:46pm, Thursday, 02'nd May 2024
Ardelyx (ARDX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.13 per share a year ago.
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
04:02pm, Thursday, 02'nd May 2024
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:07am, Thursday, 25'th Apr 2024
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Millionaire's Shortcut: 3 Stocks to Transform Your Portfolio This Month
11:34am, Tuesday, 02'nd Apr 2024
The stock market has performed remarkably well lately. Within the last 12 months, the S&P 500, a benchmark representation of the U.S. stock market comprised of the 500 largest publicly traded companie
Ardelyx, Inc. Reports Employment Inducement Grants
04:05pm, Thursday, 28'th Mar 2024
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class m
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
08:00am, Monday, 25'th Mar 2024
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
Bull Signal Says Buy This Biopharmaceutical Stock Now
02:08pm, Thursday, 21'st Mar 2024
Ardelyx Inc (NASDAQ:ARDX) stock was last seen 0.6% lower at $7.75, extending a pullback from its Feb. 12, nearly seven-year high of $10.13.
The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter
06:00pm, Saturday, 16'th Mar 2024
Finding the next great investment is alluring, almost like a siren's song. For this, one must possess a crystal ball to identify the stocks about to soar, elevating portfolios to unprecedented heights
